Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2037.0
(-2.72%)
JPY 2037.0
(-2.72%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 25.43 Billion JPY | 29.92% |
| 2022 | 19.58 Billion JPY | 13.39% |
| 2021 | 17.26 Billion JPY | 9.14% |
| 2020 | 15.82 Billion JPY | -8.97% |
| 2019 | 17.38 Billion JPY | 12.87% |
| 2018 | 15.39 Billion JPY | -17.65% |
| 2017 | 18.7 Billion JPY | -6.0% |
| 2016 | 19.89 Billion JPY | 0.58% |
| 2015 | 19.77 Billion JPY | -3.28% |
| 2014 | 20.45 Billion JPY | 1.9% |
| 2013 | 20.07 Billion JPY | 1.94% |
| 2012 | 19.68 Billion JPY | 7.04% |
| 2011 | 18.39 Billion JPY | -1.66% |
| 2010 | 18.7 Billion JPY | 3.5% |
| 2009 | 18.07 Billion JPY | -7.98% |
| 2008 | 19.63 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 29.84 Billion JPY | 17.32% |
| 2023 Q2 | 22.86 Billion JPY | 13.3% |
| 2023 FY | 25.43 Billion JPY | 29.92% |
| 2023 Q3 | 25.3 Billion JPY | 10.65% |
| 2023 Q4 | 25.43 Billion JPY | 0.53% |
| 2023 Q1 | 20.18 Billion JPY | 3.08% |
| 2022 Q1 | 20.71 Billion JPY | 19.93% |
| 2022 FY | 19.58 Billion JPY | 13.39% |
| 2022 Q4 | 19.58 Billion JPY | 4.42% |
| 2022 Q3 | 18.75 Billion JPY | -13.17% |
| 2022 Q2 | 21.59 Billion JPY | 4.28% |
| 2021 FY | 17.26 Billion JPY | 9.14% |
| 2021 Q1 | 15.38 Billion JPY | -2.75% |
| 2021 Q2 | 16.31 Billion JPY | 6.04% |
| 2021 Q3 | 16.37 Billion JPY | 0.37% |
| 2021 Q4 | 17.26 Billion JPY | 5.45% |
| 2020 Q2 | 16.41 Billion JPY | 7.95% |
| 2020 Q3 | 17.75 Billion JPY | 8.13% |
| 2020 Q4 | 15.82 Billion JPY | -10.88% |
| 2020 Q1 | 15.2 Billion JPY | -12.5% |
| 2020 FY | 15.82 Billion JPY | -8.97% |
| 2019 Q3 | 17.27 Billion JPY | 6.06% |
| 2019 FY | 17.38 Billion JPY | 12.87% |
| 2019 Q4 | 17.38 Billion JPY | 0.63% |
| 2019 Q1 | 16.43 Billion JPY | 6.75% |
| 2019 Q2 | 16.28 Billion JPY | -0.94% |
| 2018 FY | 15.39 Billion JPY | -17.65% |
| 2018 Q3 | 18.7 Billion JPY | 0.52% |
| 2018 Q2 | 18.61 Billion JPY | 1.3% |
| 2018 Q1 | 18.37 Billion JPY | -1.75% |
| 2018 Q4 | 15.39 Billion JPY | -17.69% |
| 2017 Q2 | 20.36 Billion JPY | 0.59% |
| 2017 FY | 18.7 Billion JPY | -6.0% |
| 2017 Q4 | 18.7 Billion JPY | -2.88% |
| 2017 Q3 | 19.25 Billion JPY | -5.45% |
| 2017 Q1 | 20.24 Billion JPY | 1.76% |
| 2016 Q4 | 19.89 Billion JPY | -2.15% |
| 2016 FY | 19.89 Billion JPY | 0.58% |
| 2016 Q1 | 19.27 Billion JPY | -2.53% |
| 2016 Q3 | 20.33 Billion JPY | -0.22% |
| 2016 Q2 | 20.37 Billion JPY | 5.69% |
| 2015 Q4 | 19.77 Billion JPY | -7.54% |
| 2015 Q3 | 21.39 Billion JPY | 12.3% |
| 2015 Q2 | 19.04 Billion JPY | -3.36% |
| 2015 FY | 19.77 Billion JPY | -3.28% |
| 2015 Q1 | 19.71 Billion JPY | -3.62% |
| 2014 Q1 | 20.62 Billion JPY | 2.77% |
| 2014 Q3 | 19.66 Billion JPY | -2.85% |
| 2014 Q4 | 20.45 Billion JPY | 4.01% |
| 2014 FY | 20.45 Billion JPY | 1.9% |
| 2014 Q2 | 20.23 Billion JPY | -1.88% |
| 2013 Q1 | 20.26 Billion JPY | 2.93% |
| 2013 Q3 | 18.58 Billion JPY | -8.67% |
| 2013 Q4 | 20.07 Billion JPY | 7.98% |
| 2013 FY | 20.07 Billion JPY | 1.94% |
| 2013 Q2 | 20.34 Billion JPY | 0.42% |
| 2012 Q1 | 20.49 Billion JPY | 11.4% |
| 2012 FY | 19.68 Billion JPY | 7.04% |
| 2012 Q3 | 20.68 Billion JPY | 1.05% |
| 2012 Q2 | 20.46 Billion JPY | -0.13% |
| 2012 Q4 | 19.68 Billion JPY | -4.8% |
| 2011 Q1 | 19.5 Billion JPY | 4.27% |
| 2011 Q2 | 19.43 Billion JPY | -0.37% |
| 2011 FY | 18.39 Billion JPY | -1.66% |
| 2011 Q3 | 19.56 Billion JPY | 0.69% |
| 2011 Q4 | 18.39 Billion JPY | -6.0% |
| 2010 Q2 | 18.61 Billion JPY | 1.41% |
| 2010 Q4 | 18.7 Billion JPY | -2.95% |
| 2010 Q3 | 19.27 Billion JPY | 3.52% |
| 2010 FY | 18.7 Billion JPY | 3.5% |
| 2010 Q1 | 18.35 Billion JPY | 0.0% |
| 2009 FY | 18.07 Billion JPY | -7.98% |
| 2008 FY | 19.63 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | -1.805% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.675% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 96.614% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 84.522% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -649.312% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 40.657% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 8.71% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 94.859% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | -404.742% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 58.766% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 17.492% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 36.073% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 18.16% |
| Tsumura & Co. | 132.88 Billion JPY | 80.857% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 36.068% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | -91.314% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 90.741% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 42.391% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 64.021% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 45.751% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | -263.259% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | -212.436% |
| MedRx Co., Ltd | 129 Million JPY | -19620.155% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -677.348% |
| Solasia Pharma K.K. | 673 Million JPY | -3679.941% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -3840.958% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 18.935% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 84.488% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -2415.376% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 95.145% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | -265.906% |